Assembly Biosciences, Inc.:
Focused on targeting hepatitis B virus (HBV) with a portfolio of potent, oral core inhibitors, that have the potential to increase cure rates for chronically infected patients. Lead candidate 731 is in Phase 2 – has demonstrated a favorable safety profile, and decreases in cccDNA population with patients expected to be withdrawn from treatment in 2020 and followed for sustained viral DNA suppression off therapy. 2158 is expected to complete Phase 1b in Q1 2020.
US - East North Central
Phase l or ll
Anti-infectives, Antivirals, Gastrointestinal, Infectious Disease
500MM - 1B
11711 North Meridian Street
Carmel, IN 46032
Top 10 Holders of Assembly Biosciences, Inc.
Ownership data is sourced through FactSet.
Stock Market Data
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by